Clinical Trials Logo
  1. Home
  2. Dyskinesias
  3. NCT05516875

Open-Label Extension Study of ASTORIA

Dyskinesias Clinical Trial

Official title:
Open-Label Extension Study of JM-010 in Parkinson's Disease Patients With Dyskinesia

Clinical Trial Summary

This current open-label extension (OLE) study (JM-010CS-OL) will explore the safety and tolerability of long-term administration of JM-010 of patients who completed 12-week treatment of Phase 2 (JM-010CS03) study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05516875
Study type Interventional
Source Contera Pharma A/S
Contact Contera Clinical Development
Phone 82-2-828-8114
Email cp.e103@conterapharma.co.kr
Status Not yet recruiting
Phase Phase 2
Start date January 31, 2023
Completion date October 30, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT00986414 - Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease Phase 2
Terminated NCT03270189 - Effect of the Visual Information Change in Functional Dystonia N/A
Completed NCT05044572 - Comparison of Open Chain Kinetic Exercises and Forward Head Posture Correction in Type II Scapular Dyskinesia N/A
Completed NCT01474421 - Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease Phase 2
Suspended NCT04912115 - Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia Phase 2
Recruiting NCT05116813 - Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy Phase 2/Phase 3
Completed NCT01385592 - Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias Phase 2
Completed NCT01491932 - Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias Phase 2
Completed NCT00086294 - ACP-103 to Treat Parkinson's Disease Phase 2
Completed NCT00360568 - Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects Phase 3
Recruiting NCT05317390 - Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia N/A
Active, not recruiting NCT03956979 - A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia Phase 2
Active, not recruiting NCT04453995 - A Follow-up of the Influencing Factors of Dyskinesia in Patients With Parkinson's Disease
Terminated NCT02589340 - Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia Phase 1
Completed NCT00076674 - Levetiracetam Treatment of L-dopa Induced Dyskinesias Phase 2
Completed NCT00888186 - Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics Phase 4
Completed NCT00004576 - Study of LY300164 for the Treatment of Parkinson's Disease Phase 2
Completed NCT00036296 - Effects of Talampanel on Patients With Advanced Parkinson's Disease Phase 1/Phase 2
Completed NCT00363727 - Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's Phase 3
Recruiting NCT04857359 - Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy Phase 2/Phase 3